Posts

The European Union’s drug regulator said on Tuesday it has started a review to extend the use of Bavarian Nordic’s (BAVA.CO) smallpox vaccine to prevent monkeypox disease as well.

Bavarian Nordic announced Thursday that the upcoming Phase III trial for ABNCoV2, the Denmark-based biotech company’s COVID-19 booster candidate, has been redesigned to compete against Pfizer-BioNTech’s mRNA-based vaccine.

Bavarian Nordic raised the company’s financial guidance for 2022 for the third time in a month on Friday after receiving a large order for its monkeypox vaccine by the U.S. Biomedical Advanced Research and Development Authority (BARDA).

The European Union is working on a common purchasing agreement for vaccines and antivirals against monkeypox, as cases of the viral disease usually endemic to Africa gather steam in Europe and beyond.